Product images are for illustration purposes only. Actual packaging and labelling may vary.
Buy BPC-157 / TB-500 Blend 10mg Australia
★★★★★4.6 · 7 reviewsResearch Use Only: For laboratory research purposes only. Not for human or animal consumption.
Description
This blend combines BPC-157 (5mg) and TB-500/Thymosin Beta-4 fragment (5mg) in a single lyophilised vial, enabling co-administration research of two complementary tissue-repair peptides. BPC-157 acts via VEGFR2-ERK1/2 and nitric oxide pathways to promote angiogenesis and fibroblast activity, while TB-500 (the 43-amino-acid synthetic analogue of Thymosin Beta-4) functions primarily as an actin-sequestering protein that regulates G-actin/F-actin dynamics, cell migration, and endothelial differentiation. TB-500 is also studied for its anti-inflammatory properties via TLR4/MyD88 pathway modulation and its role in reducing apoptosis in neural and cardiac tissue. Preclinical evidence supports synergistic effects on soft tissue repair when both peptides are studied together. Suited for researchers investigating multi-pathway regenerative signalling in musculoskeletal, vascular, or neurological models. Total peptide content 10mg per vial. CAS BPC-157: 137525-51-0 | CAS TB-500: 77591-33-4. For research use only. Not for human consumption.
BPC-157 / TB-500 Blend
The BPC-157/TB-500 combination pairs two of the most studied peptides in musculoskeletal and wound healing research. This 10mg blend vial contains equal-ratio BPC-157 and TB-500, pre-blended for research convenience.
BPC-157 and TB-500 operate through distinct but complementary mechanisms. BPC-157 primarily drives angiogenesis via VEGF upregulation, activates FAK/paxillin signalling for cell migration, and exerts cytoprotective effects in gastrointestinal and hepatic tissue. TB-500 works through Thymosin Beta-4's actin-sequestering domain to regulate cytoskeletal remodelling and promote endothelial migration, with particular documented activity in cardiac tissue.
Why the Combination?
The scientific rationale for combining BPC-157 and TB-500 lies in the additive and complementary nature of their mechanisms. Both promote angiogenesis, but through different upstream pathways (VEGF-mediated for BPC-157, endothelial migration-mediated for TB-500), potentially producing additive vascularisation effects.
Both compounds independently reduce local inflammatory markers in their respective model systems. Their tissue specificity is also complementary: BPC-157's strongest evidence base is in tendon, ligament, and gastrointestinal models; TB-500's extends to cardiac and skeletal muscle, giving the combination broader coverage than either compound alone.
Research combining the two compounds has consistently shown outcomes that exceed either compound individually in musculoskeletal healing models. Supplied for laboratory research use only.
Reconstitution & Storage
Reconstitute the blend with bacteriostatic water, 2ml per 10mg vial gives 5mg/ml. Add water slowly down the vial wall and gently swirl. Store lyophilised at −20°C; reconstituted solution at 2–8°C for up to 4 weeks.
Research Guide Available , read the science, mechanism, and research data for this compound.
Frequently Asked Questions
Research Use Only: This product is for laboratory research purposes only. Not for human consumption. All compounds are sourced from suppliers with a verified Certificate of Analysis (COA).
Customer Reviews
Turned around fast, no fuss.
Easy to order, quick delivery
Solid product, no complaints